참고문헌
- Bai W, Wang YJ, Zhao Y, et al (2013). Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis, 14, 181-90. https://doi.org/10.1111/1751-2980.12038
- Brunocilla PR, Brunello F, Carucci P, et al (2013). Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol, 30, 345. https://doi.org/10.1007/s12032-012-0345-2
- Chang MH, Chen CJ, Lai MS, et al (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med, 336, 1855-9. https://doi.org/10.1056/NEJM199706263362602
- Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised,doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
- Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- European Association for Study of Liver; European Organisation for Research and Treatment of Cancer (2012). EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer, 48, 599-641. https://doi.org/10.1016/j.ejca.2011.12.021
- Ezzoukhry Z, Louandre C, Trecherel E, et al (2012). EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer, 131, 2961-9. https://doi.org/10.1002/ijc.27604
- Huynh H, Nguyen TT, Chow KH, et al (2003). Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol, 3, 19. https://doi.org/10.1186/1471-230X-3-19
- Kostner AH, Sorensen M, Olesen RK, et al (2013). Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorld Journal, 2013, 931972.
- Llovet JM, Ricci S, Mazzaferro V, et al (2008); Sharp investigators study group. sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
- Oliveri RS, Wetterslev J, Gluud C (2011). Transarterial(chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev, 16, 4787.
- Schmitt M, Horbach A, Kubitz R, et al (2004). Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol, 41, 274-83 https://doi.org/10.1016/j.jhep.2004.04.035
- Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
- Stock P, Monga D, Tan X, et al (2007). Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther, 6, 1932-41.
- Zhu AX, Rosmorduc O., Evans J, et al (2012). A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). 37th ESMO Congress; Vienna, Austria. European Society Med Oncol.
피인용 문헌
- Clinical Significance of Joint Detection of Serum VEGF, SIL-2R and HGF in Patients with Primary Hepatocellular Carcinoma before and after Percutaneous Microwave Coagulation Therapy vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4545
- Differential Expression of IQGAP1/2 in Hepatocellular Carcinoma and its Relationship with Clinical Outcomes vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4951
- Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5691
- Clinical Study of Hepatectomy Combined with Jianpi Huayu Therapy for Hepatocellular Carcinoma vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5951
- Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3151
- Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3651
- Health-Related Quality of Life of Patients with Intermediate Hepatocellular Carcinoma after Liver Resection or Transcatheter Arterial Chemoembolization vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4451
- Activation of Caspase-9/3 and Inhibition of Epithelial Mesenchymal Transition are Critically Involved in Antitumor Effect of Phytol in Hepatocellular Carcinoma Cells vol.29, pp.7, 2015, https://doi.org/10.1002/ptr.5342
- Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3707-5
- Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals vol.8, pp.10, 2017, https://doi.org/10.1038/cddis.2017.411
- Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells pp.1432-0738, 2018, https://doi.org/10.1007/s00204-017-2021-y
- Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence vol.13, pp.2, 2016, https://doi.org/10.3892/ol.2016.5525
- altering the pSTAT3-CCL2/Bcl2 signals vol.140, pp.3, 2016, https://doi.org/10.1002/ijc.30446
- Wogonin Suppresses the Activity of Matrix Metalloproteinase-9 and Inhibits Migration and Invasion in Human Hepatocellular Carcinoma vol.23, pp.2, 2018, https://doi.org/10.3390/molecules23020384
- Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study vol.6, pp.5, 2018, https://doi.org/10.12998/wjcc.v6.i5.74